随着医药反腐升级，国内很多健康类公司搁置了上市计划。请看本报昨日的报道：

A growing number of health care companies in China are shelving their initial public offering (IPO) plans as the country’s stock exchanges have stepped up scrutiny of the pharmaceutical industry’s business practices amid an escalating anti-corruption drive.

Health care stocks have already slumped in China since the government in late July launched a year-long anti-graft campaign, targeting what it said was the rampant practice of bribing of doctors in drug and medical equipment sales.

报道中的anti-graft campaign就是“反腐行动”，也可以说anti-corruption drive。